Browse the evidence

Diabetes management is being transformed by continuous glucose monitoring (CGM) systems and closed-loop insulin delivery.

Healthcare providers should adopt CGM systems and closed-loop delivery for improved diabetes management.

Bariatric surgery is the most cost-effective definitive treatment for all classes of obesity.

Healthcare systems should prioritize bariatric surgery as a treatment option for obesity.

Participants enrolling during program periods with access to a larger number of stores had ≤14.5% absolute higher redemption rates and 5-fold greater likelihood of shopping each month than those enrolled with fewest locations.

Increasing the number of stores available for produce prescription programs may enhance redemption rates and shopping frequency.

Redemption rates increased over time for participants in the program, rising from 31% in month 1 to 88% in month 24.

Longer participation in produce prescription programs is associated with significantly higher redemption rates.

Effects on gastric emptying appeared additive when BI 1820237 was combined with low-dose liraglutide.

Combining BI 1820237 with liraglutide may enhance effects on gastric emptying, which could be relevant for treatment strategies.

Some people with HIV treated with antiretroviral therapy gain unhealthy amounts of weight and develop consequences of obesity.

Healthcare providers should monitor weight changes in PWH on ART.

There is a strong need for multimodal therapeutic approaches to address obesity.

Therapists should implement diverse strategies to effectively manage obesity.

The combination of long-acting PYY analogs with a GLP-1 receptor agonist resulted in superior blood glucose lowering and greater body weight loss compared to GLP-1 alone.

Suggests a potential strategy for enhanced diabetes and obesity treatment.

Co-agonism of the glucagon and GLP-1 receptors improves glycemia in people with diabetes and obesity.

Practitioners may consider glucagon and GLP-1 receptor co-agonists as a treatment option for improving glycemia.

There are no indications of additional risk for people with HIV using liraglutide and semaglutide.

Liraglutide and semaglutide can be considered safe for use in HIV patients without additional risk.

Employment increased by 2.9 percentage points for the intensive lifestyle intervention (ILI) group relative to controls.

Implementing intensive lifestyle interventions may improve employment rates among individuals with type 2 diabetes.

An intensive lifestyle intervention was associated with higher levels of employment.

Healthcare providers should consider lifestyle interventions as a means to improve employment outcomes for patients with type 2 diabetes.

Patients exhibited initial physical functioning scores below the reference values yet demonstrated substantial physical recuperation by the 12-week mark following their ICU discharge in both groups.

Nutrition interventions may play a crucial role in recovery for post-ICU patients.

Hormonal and immune responses to acute exercise were similar over time and between groups.

Practitioners can expect similar hormonal and immune responses regardless of protein supplementation during concurrent training.

Continuous glucose monitoring can provide benefits when initiating GLP-1RA treatment.

Implementing continuous glucose monitoring can enhance the safety and effectiveness of GLP-1RA therapy.

Haemoglobin A1c (HbA1c) was significantly reduced at 12 months but not at 24 months.

Monitoring HbA1c levels can help assess the effectiveness of dietary interventions in T2DM.

The 7-year cardiovascular risk was 18.0% in the bariatric surgery group and 18.9% in the no-surgery group, with a risk difference of -0.9.

Bariatric surgery may not significantly reduce cardiovascular risk in this population.

Participants with higher susceptibility to external eating cues may be more responsive to the intervention.

Tailoring interventions to address external eating cues may enhance effectiveness for certain individuals.

The gut is a promising target for therapeutic interventions to achieve significant weight loss.

Practitioners should consider gut-targeted therapies as viable options for obesity treatment.

Current evidence indicates similar whole muscle hypertrophy between multi-joint (MJ) and single-joint (SJ) training.

Both MJ and SJ exercises can be effective for muscle growth.

There may be added benefit to combining SJ and MJ exercises for targeting individual aspects of a given muscle.

Combining SJ and MJ exercises may enhance muscle development.

Moderate-quality evidence revealed beneficial relationships between the intake of omega-6 fatty acids and cardiovascular disease (CVD) mortality, overall cancer mortality, and all-cause mortality.

Increasing omega-6 fatty acid intake may reduce risks of CVD and cancer.

Moderate-quality evidence suggested that seafood-derived omega-3 fatty acids were associated with reduced triglyceride levels, elevated high density lipoprotein cholesterol, and a decreased risk of coronary heart disease.

Encouraging seafood consumption may improve heart health and lipid profiles.

A significant global prevalence of inadequate omega-6 and seafood omega-3 fatty acid intakes exists, particularly in less-developed regions.

Efforts should be made to improve omega-6 and omega-3 intake in less-developed areas.